ReviewToxins2016
Bee Venom Phospholipase A2: Yesterday's Enemy Becomes Today's Friend.
Review in Toxins, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Pooled it
- Clinical Effectiveness and Adverse Events of Bee Venom Therapy: A Systematic Review of Randomized Controlled Trials.Toxins · 2020Pooled it
- Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical Trial.PloS one · 2016Trial
- Inhibitory Mechanism of Bee Venom Against A431 Cutaneous Squamous Cell Carcinoma Cells Based on Label-Free Proteomics and Untargeted Metabolomics.International journal of molecular sciences · 2026Article
- Mechanisms of In Vitro Cytotoxicity of Honeybee Venom Components and Melittin-Functionalized FeMaterials (Basel, Switzerland) · 2026Article
- From Toxin to Therapy: Biomedical Applications of Bee Venom in Cancer, Diabetes, and Neurodegenerative Disorders.International journal of molecular sciences · 2026Review
- Ruthenium Compounds Differentially Inhibit Group IA and IIA Snake Venom Phospholipase AInternational journal of molecular sciences · 2026Article
- Article
- Pharmacological characterization and nephroprotective potential of venoms from three egyptian scorpion species.Frontiers in pharmacology · 2026Article
- Enzymatic characterization and proteomic profiling of venoms from the medically important Androctonus species.Journal, genetic engineering & biotechnology · 2025Article
- In Vitro and In Vivo Comparative Analysis of Muscle Regenerative Processes Induced by Different Microcurrent Waveforms in Skeletal Muscle Atrophy.International journal of molecular sciences · 2025Article
- The Effect of Bee Venom and Melittin on Glioblastoma Cells in Zebrafish Model.Molecules (Basel, Switzerland) · 2025Article
- Anticancer Activity of Melittin-Containing Bee Venom Fraction Against Glioblastoma Cells In Vitro.International journal of molecular sciences · 2025Article
- Review
- Article
- Bee Venom: Composition and Anticancer Properties.Toxins · 2024Review
- Harnessing the power of bee venom for therapeutic and regenerative medical applications: an updated review.Frontiers in pharmacology · 2024Review
- Melittin as a therapeutic agent for rheumatoid arthritis: mechanistic insights, advanced delivery systems, and future perspectives.Frontiers in immunology · 2024Review
- Bee Venom and Its Two Main Components-Melittin and Phospholipase A2-As Promising Antiviral Drug Candidates.Pathogens (Basel, Switzerland) · 2023Review
- Pharmacokinetics and Tissue Distribution of Bee Venom-Derived Phospholipase A2 Using a Sandwich ELISA after Subcutaneous Injection of New Composition Bee Venom in Rats.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bee venom therapy has been used to treat immune-related diseases such as arthritis for a long time. Recently, it has revealed that group III secretory phospholipase A2 from bee venom (bee venom group III sPLA2) has in vitro and in vivo immunomodulatory effects. A growing number of reports have demonstrated the therapeutic effects of bee venom group III sPLA2. Notably, new experimental data have shown protective immune responses of bee venom group III sPLA2 against a wide range of diseases including asthma, Parkinson's disease, and drug-induced organ inflammation. It is critical to evaluate the beneficial and adverse effects of bee venom group III sPLA2 because this enzyme is known to be the major allergen of bee venom that can cause anaphylactic shock. For many decades, efforts have been made to avoid its adverse effects. At high concentrations, exposure to bee venom group III sPLA2 can result in damage to cellular membranes and necrotic cell death. In this review, we summarized the current knowledge about the therapeutic effects of bee venom group III sPLA2 on several immunological diseases and described the detailed mechanisms of bee venom group III sPLA2 in regulating various immune responses and physiopathological changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.